Multitude Therapeutics Inc.

Quick facts

Phase 2 pipeline

• AMT-676 · Nephrology / Endocrinology
  AMT-676 is a small-molecule allosteric modulator of the calcium-sensing receptor (CaSR) that enhances receptor sensitivity to extracellular calcium.

Phase 1 pipeline

• AMT-116
• AMT-151

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Multitude Therapeutics Inc. portfolio CI brief
• Multitude Therapeutics Inc. pipeline updates RSS